Fibroblast growth factors (FGF) 19, 21, and 23 have been reported as functional factors in human metabolic diseases and malignancies. We performed a prospective survey to compare circulating FGF levels in urothelial carcinoma (UC) patients and normal controls. Between 2016 and 2017, 39 patients with UC of the urinary bladder or upper urinary tract who received surgical intervention were included. All the serum samples were obtained before surgeries. The control group included 28 healthy volunteers. Analysis of the circulating FGF19, 21, and 23 levels among all 67 subjects, as well as a subgroup analysis of the 39 UC patients were performed. The median levels of serum FGF19, 21, and 23 in the UC patients were 84.2, 505.3, and 117.6 pg/mL, respectively, which were statistically different from levels found in the healthy controls (P = 0.015, <0.001 and < 0.001, respectively). In the subgroup analysis, the FGF19 and FGF21 levels were significantly higher in end-stage renal disease UC patients, while FGF21 was also higher in the UC patients with cardiovascular diseases and history of recurrent UC. In the receiver operating characteristic (ROC) curve analysis, FGF19, 21, and 23 were all significant predictors of UC [area under the curve (AUC)] 0.674, P = 0.015; AUC 0.918, P < 0.001; AUC 0.897, P < 0.001, respectively). In UC patients, serum FGF19 level was significantly lower, while FGF21 and 23 were significantly higher, than respective levels in healthy controls. All three markers may serve as good predictors of UC occurrence, and FGF21 level was associated with disease recurrence. © 2018 BioFactors, 45(1):62-68, 2019
Introduction
Fibroblast growth factors (FGFs) are capable of attenuating multiple signaling transduction pathways and are key factors in numerous human biological processes [1, 2] . The mechanism of action is mainly through ligand receptors and subsequent activation of downstream signal transduction cascades involving FGF-binding proteins [3] . Among them, FGF19, 21, and 23 are considered special subsets with hormonal endocrine function, which are involved in glucose metabolism, bile synthesis, and homeostasis of serum calcium and phosphate [4] [5] [6] . Moreover, this subset of FGF has also been reported to exhibit tumorigenesis potential. FGF19 was shown to be involved in the carcinogenesis of hepatocellular carcinoma, and colon cancer [7] . FGF21 was reported to be overexpressed in hepatocellular carcinoma as well as kidney cancer [8, 9] . Moreover, FGF23 was found to promote prostate cancer cell growth and invasion [10] . All three hormonal FGFs activate the transmembrane tyrosine kinase receptors with the help of cofactors, Klotho proteins [11, 12] . Although FGF19, 21, and 23 are derived from intestine, liver, and bone, respectively, the systemic effects are not well identified, and its role in the tumorigenesis of urothelial carcinoma (UC) has yet to be fully elucidated. Herein, we evaluate circulating FGF19, 21, and 23 in UC patients and identify correlations with clinical variables.
Materials and methods

Patients and study design
Thirty-nine patients who received surgeries for UC in Taichung Veterans General Hospital between 2016 and 2017 were enrolled in this study. The study protocol was reviewed and approved by the Institutional Review Board of Taichung Veterans General Hospital, number CE16083B. All enrolled patients received standard transurethral resection or radical cystectomy for bladder tumor (UCUB) or nephroureterectomy for upper urinary tract tumor (UTUC) according to the clinical relevance. Patients who had a history of receiving systemic chemotherapy, immunotherapy, or targeted therapy for UC were excluded, except those who received local bladder instillation therapy. Blood samples were collected from the antecubital vein after an overnight fast before the surgical procedure in the operation room. Blood samples were processed to obtain serum and aliquoted and stored at −70 C until analysis. Measurement of FGF19, 21, and 23 serum level by enzymelinked immunosorbent assay (ELISA). Plasma levels of FGF19 (R&D Systems, Minneapolis, MN), FGF21 (R&D Systems), and FGF23 (Cloud-Clone Corp., Wuhan, Hubei, China) were measured using ELISA kits according to the manufacturers' instructions.
Study assessment
All patients' clinical characteristics were recorded including age, sex, tumor sites, T stage, nodal status, metastasis status, tumor grading, surgery type, overall comorbidities, hypertension under treatment, cardiovascular diseases (CAD), diabetes mellitus (DM), chronic kidney disease (CKD), end-stage renal disease (ESRD), and history of recurrent UC. The tumor sites were recorded according to the presence of UTUC or UBUC, and UTUC was recorded if both types were present. The T stages were recorded according to the American Joint Committee on Cancer (AJCC) 8th edition and the highest stage was recorded for multiple tumors. The nodal and metastasis status were recorded according to the AJCC classification. The tumor grading was recorded using the final pathology reports according to the WHO classification in 2016. The surgery type included transurethral resection of bladder tumor (TURBt), radical cystectomy and nephroureterectomy for UTUC. Overall comorbidities included hypertension, CAD, DM, and CKD. The definition of hypertension was based on the clinical diagnosis in medical records and prescription of antihypertensive medications. The diagnosis of CAD was based on chart records and prescription of anti-coagulants or nitroglycerin. The definition of DM was based on medical records and the use of insulin or hypoglycemic agents. CKD was defined as a pre-operative estimated glomerular filtration rate lower than 60 ml/min/1.73 m 2 .
The definition of ESRD was based on medical records showing persistent hemodialysis or peritoneal dialysis. The definition of history of recurrent UC was based on medical records showing at least two surgical treatments for UC. The Mann-Whitney U test was used for nonparametric comparison of the serum FGF level between the normal controls and the UC patients, as well as the subgroup differences in the UC group. The differences among the three groups were analyzed using the Kruskal-Wallis test for continuous variables. The area under the curve (AUC) was calculated by receiver operating characteristic curve (ROC) analysis to predict accuracy of FGF19, 21, and 23 in UC patients compared with normal controls. All statistical analyses were performed using SAS software version 9.2 (SAS Institute, Inc., Cary, NC). A P value of <0.05 was considered statistically significant. Table 1 displays a comparison of the serum FGF level between the normal controls and the UC patients. FGF19 was significantly lower in the UC patients than in the normal controls (84.2 vs. 168.3 pg/mL, P = 0.015). FGF21 and 23 were significantly higher in the UC patients than in the normal controls (505.3 vs. 128.5 pg/mL, P < 0.001; 117.6 vs. 71.0 pg/mL, P < 0.001, respectively). The subgroup analysis of the UC patients' FGF 19, 21, and 23 levels showed no differences in age, gender, grade, tumor sites, T stage, N status, M status, surgery type, overall morbidity, hypertension, DM, and CKD (Table 2 ). FGF21 revealed a significant increase in CAD patients (863.2 vs. 440.1 pg/mL, P = 0.024). Among ESRD patients, both FGF19 and 21 were significantly elevated (P = 0.001 and P = 0.004, respectively). We also found FGF21 was increased in patients with history of recurrence (P = 0.025).
Results
The ROC analysis showed FGF21 had the highest AUC (0.918) with sensitivity of 84.62% and specificity of 89.29%, while the AUC for FGF23 was 0.897 with sensitivity of 87.18% and specificity 82.14% (Fig. 1 ). The AUC of FGF 19 was 0.674 with sensitivity 87.18% and specificity of only 50%. When the data of FGF21 and 23 were combined, a higher specificity was obtained (96.43%), but the sensitivity decreased to 72.5%.
Discussion
Our study is the first series to report associations between hormonal FGFs and UC. FGF21 and 23 showed a significant increase in UC patients, while FGF19 was significantly decreased compared with normal controls. This finding suggests that FGFs may have use as a predictive marker for UC and therefore further research on the underlying mechanism is warranted.
The FGF family includes 22 proteins which have a wide variety of functions in angiogenesis, tissue remodeling, and neural development in mammals. They exert their effects through five FGF receptors and evoke intracellular pathways such as phosphatidylinositol 3-kinase(PI3K), mitogen-activated protein kinases (MAPK), protein kinase C, and signal transducers and activators of transcription (STATs) [2, 3] . FGF19, 21, and 23 are thought to be involved in different metabolic processes with Klotho playing a mediating role in FGF signal transduction, and studies have shown that the most commonly involved FGF receptors areFGFR1,FGFR3, and FGFR4 [11, 12] . FGF19 was reported to be involved in the regulation of bile synthesis and glucose metabolism, and has a role in insulin sensitivity [2, 4, 13] . FGF21 exerts its plasma glucose-lowering effect through the regulation of adipose tissue and was also shown to be involved in cardiovascular remodeling [6, 11] . FGF23 is a calciotrophic hormone and facilitates excretion of phosphate [5] .
The measurement of serum FGF only in our study was based on two major reasons. First, serum endocrine FGFs were already reported to show tumorigenesis effects in different cancers. However, the circulating level of endocrine FGFs in UC was not reported yet. The importance of circulating endocrine FGFs was first reported in a FGF19 overexpressed skeletal muscle mice model [7] . In the transgenic model, hepatocellular carcinoma development was observed which disclosed circulating FGFs may act as an promoter of cancer. Other series also corresponded the oncogenesis theory of endocrine FGFs and reported the association between human solid cancers and increased circulating FGFs. FGF19 was found to be involved in tumorigenesis and in the promotion of hepatocellular carcinoma, colon cancer, and prostate cancer in vitro and in vivo [7, 14, 15] . FGF21 was activated in the process of hepatocarcinogenesis and prostate cancer [8, 15] . FGF23 was reported to be associated with osteogenic osteomalacia in colon cancer and prostate cancer [10, 16] . Second, the circulating endocrine FGFs level are easily measured and reproduced. Therefore, it could be managed as a tumor marker during detection, treatment evaluation and follow-up. From previous xenograft in vivo study, an anti-FGF19 monoclonal antibody could inhibit colon cancer cell growth [17] . This study implied changes of circulating endocrine FGFs level may directly influence the cancer environment. A recent study showed FGF19 and 21 could act as biomarkers during treatment follow-up using pan-FGFR inhibitors in patients with advanced solid tumor. FGF19 and 21 were found to be increased during each treatment with a dosedependent trend, which implies that it reflects the patients' therapeutic response [18] .
In our study, FGF21 and 23 were significantly elevated in UC patients compared with levels found in normal controls. Conversely, FGF19 showed a negative association with UC. The decreased level of FGF19 may be associated with two major reasons. First, FGF19 was reported a physiological function to ameliorate skeletal muscle waste in mice [19] . Downregulation of FGF19 may be associated with the status of sarcopenia in the UC patient group, since 66.7%(26/39) of them had muscle invasive diseases. Furthermore, diabetes and low visceral fat condition may also be associated with lower FGF19 level in previous studies [20, 21] . All above reasons could be the possible confounding factors of FGF19 downregulation in UC patients. Previous studies have already shown FGFs/FGFRs can mediate tumorigenesis and anti-apoptosis, as well as promote epithelial-mesenchymal transition and angiogenesis [16, 17] . The role of aberrant FGFRs in the development of cancer has been established and they are therefore new therapeutic targets. It is believed that FGFRs rather than FGFs are the key component of subsequent signal transduction in cancer [22] . Parish et al. applied next-generation sequencing techniques and showed a co-localized over-expression mutation of FGFs/ FGFRs in multiple solid tumors [23] . This phenomenon occurred in a low percentage of solid tumors, ranging from 10 to 30%, which corresponds to the minor role of FGFs. Although FGFs have been shown to involve autocrine and paracrine mechanisms in in vitro experiments, it is still difficult to determine the precise role of FGFs in humans [16] . Furthermore, our results revealed high associations of serum FGF21 and 23 levels with UC. ROC analysis showed an AUC of 0.918 for FGF21 and an AUC of 0.897 for FGF23, which was far more sensitive and specific than in previously published series on the ability of FGFs to predict cancers [24] .
The subgroups analysis did not show any associations of FGFs with clinical tumor parameters, including TNM staging and tumor grading, with the exception of history of any tumor recurrence, which was found to be associated with elevated FGF21 level. FGFs were found to be associated with ESRD and CAD, which is consistent with our current understanding of endocrine or metabolic FGFs [25] [26] [27] [28] . Elevation of FGF19 and 21 were associated with higher incidence of ESRD. This finding is in line with previous studies which revealed FGF19 and FGF21 were indicators of chronic renal diseases. Circulating FGF19 may be associated with oxidative stress while increased FGF21 may be related to decreased renal excretion as a result of impaired renal function status. In addition, FGF21 was significantly increased among UC patients with CAD. These results are consistent with the mixed findings reported by Lee et al. and Mahabadi et al., which indicated elevated serum FGF21 can induce hyperlipidemia and may therefore be associated with coronary calcification and CAD in human subjects [29, 30] . The associations of FGF19 and FGF21 with ESRD as well as FGF21 and CAD in our series suggest that levels of these FGFs could serve as biomarkers given that endocrine FGFs are commonly associated with metabolic diseases. The subgroup analysis ofUC patients revealed that individuals who had no metabolic diseases still had higher levels of FGF21 and FGF23, as well as a lower level of FGF19 compared with normal controls. This finding showed that endocrine FGFs were consistent and reliable predictive biomarkers for UC.
There are some limitations in our study. First, only serum FGF19, 21, and 23 without FGFRs were assessed in UC patients. Levels of serum FGFRs and tumor FGFR expression were not determined. The associations between serum FGFs and FGFRs were not clearly established. Second, FGF19, 21 and 23 are endocrine FGFs, but we did not measure patients' dynamic intestinal function, liver function, or other endocrine functions. The associations between various clinical variables and serum FGFs levels should be elucidated in future studies. Third, the small numbers of patients in this study may have resulted in loss of power, and therefore, further research with a larger number of patients is required to avoid any statistical bias.
Conclusion
Endocrine FGF19, 21, and 23 may have the potential to serve as tumor markers in the detection of UC. Both FGF21 and 23 exhibited high sensitivity and specificity in the detection of treatment-naive UC patients. Our results provide evidence that these hormonal FGFs may have value as new predictive biomarkers in UC.
